160 related articles for article (PubMed ID: 9309400)
61. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
62. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.
Heitmiller RF; Redmond M; Hamilton SR
Ann Surg; 1996 Jul; 224(1):66-71. PubMed ID: 8678620
[TBL] [Abstract][Full Text] [Related]
63. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Schmidt MK; Meurer L; Volkweis BS; Edelweiss MI; Schirmer CC; Kruel CD; Gurski RR
Dis Esophagus; 2007; 20(3):212-6. PubMed ID: 17509117
[TBL] [Abstract][Full Text] [Related]
64. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
65. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
Ozcan HEA; Anuk T; Ozden O
Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
[TBL] [Abstract][Full Text] [Related]
66. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
67. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
68. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis.
Lerut T; Coosemans W; Van Raemdonck D; Dillemans B; De Leyn P; Marnette JM; Geboes K
J Thorac Cardiovasc Surg; 1994 Apr; 107(4):1059-65; discussion 1065-6. PubMed ID: 8159027
[TBL] [Abstract][Full Text] [Related]
69. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
70. Advances in Barrett's esophagus and esophageal adenocarcinoma.
Shaheen NJ
Gastroenterology; 2005 May; 128(6):1554-66. PubMed ID: 15887151
[TBL] [Abstract][Full Text] [Related]
71. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.
Nijhawan PK; Wang KK
Gastrointest Endosc; 2000 Sep; 52(3):328-32. PubMed ID: 10968845
[TBL] [Abstract][Full Text] [Related]
72. Role of cytology in the diagnosis of Barrett's esophagus and associated neoplasia.
Saad RS; Mahood LK; Clary KM; Liu Y; Silverman JF; Raab SS
Diagn Cytopathol; 2003 Sep; 29(3):130-5. PubMed ID: 12951679
[TBL] [Abstract][Full Text] [Related]
73. Role of EUS in patients with suspected Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma: impact on endoscopic therapy.
Bartel MJ; Wallace TM; Gomez-Esquivel RD; Raimondo M; Wolfsen HC; Woodward TA; Wallace MB
Gastrointest Endosc; 2017 Aug; 86(2):292-298. PubMed ID: 27889544
[TBL] [Abstract][Full Text] [Related]
74. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia.
Falk GW; Rice TW; Goldblum JR; Richter JE
Gastrointest Endosc; 1999 Feb; 49(2):170-6. PubMed ID: 9925694
[TBL] [Abstract][Full Text] [Related]
75. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
76. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
77. Histology of metaplasia and dysplasia in Barrett's esophagus.
Yerian L
Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733
[TBL] [Abstract][Full Text] [Related]
78. Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk.
Dunbar KB; Souza RF
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):447-459. PubMed ID: 28577766
[TBL] [Abstract][Full Text] [Related]
79. Magnified view of adenocarcinoma in short segment Barrett's esophagus treated by endoscopic mucosal resection.
Yagi K; Nakamura A; Sekine A; Tamiya Y; Oyamatsu M
Gastrointest Endosc; 2002 Feb; 55(2):278-81. PubMed ID: 11818942
[No Abstract] [Full Text] [Related]
80. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
